Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 2/20 | 0.39 |
| ▸ | PPOX | P50336 | 1/20 | 0.35 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.35 |
| ▸ | USP8 | P40818 | 2/20 | 0.33 |
| ▸ | USP7 | Q93009 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13924801 | 0.87 | S100A4 (0.42) | S100A4HSP90AA1ALDH1A1NPC1RAB9A | |
| SCHEMBL29362087 | 0.82 | ALDH1A1 (0.56) | S100A4ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1885714 | 0.82 | ALDH1A1 (0.56) | S100A4ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12640078 | 0.82 | ALDH1A1 (0.39) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1882564 | 0.76 | STAT3 (0.69) | S100A4HSP90AA1ALDH1A1NPC1RAB9A | |
| SCHEMBL29365255 | 0.76 | STAT3 (0.69) | S100A4HSP90AA1ALDH1A1NPC1RAB9A | |
| SCHEMBL45598 | 0.76 | S100A4 (0.46) | S100A4HSP90AA1ALDH1A1STAT3PPOX | |
| SCHEMBL4229683 | 0.74 | S100A4 (0.80) | S100A4HSP90AA1ALDH1A1NPC1RAB9A | |
| SCHEMBL353693 | 0.74 | S100A4 (0.80) | S100A4HSP90AA1ALDH1A1NPC1RAB9A | |
| SCHEMBL45824 | 0.74 | S100A4 (0.43) | S100A4HSP90AA1ALDH1A1MAPK1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. | 2019-08-29 | — | — | US | disclosed |
| EP-3058941-B1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2019-05-22 | — | — | EP | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-8877803-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877803-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | S100A4 3279/4885HSP90AA1 910/4885ALDH1A1 630/4885 |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, JAK2 | S100A4 3330/4885HSP90AA1 832/4885ALDH1A1 677/4885 |
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | STAT3, STAT1, JAK2 | S100A4 3540/4885HSP90AA1 830/4885ALDH1A1 545/4885 |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | S100A4 3279/4885HSP90AA1 910/4885ALDH1A1 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.